BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes

• DOI: 10.1152/ajpcell.00413.2023
• Publication Date: 2024-01-15T09:38:38Z
• Authors: Lucia Alcober-Boquet; Nico Kraus; Lisa Sophie Huber; Rajkumar Vutukuri; Dominik C. Fuhrmann; Claudia Stross; Liliana Schaefer; Klaus Scholich; Stefan Zeuzem; Albrecht Piiper; Marcel H. Schulz; Jonel Trebicka; Christoph Welsch; Cristina Ortiz
• Keywords: Lipotoxicity; Lipid droplet; Hepatic stellate cell

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) is a lipid droplet protein primarily expressed in the liver hepatocytes. HSD17B13 associated with clinical outcome of chronic diseases and therefore target for development drugs. Here, we demonstrate promising therapeutic effect BI-3231 as potent inhibitor based on its ability to inhibit triglyceride accumulation droplets (LDs), restore metabolism homeostasis, increase mitochondrial activity vitro.